**Supplementary Table 1 |** **Known mutations in the hypoxia signalling system in humans.**

|  |  |  |
| --- | --- | --- |
| Gene | Mutation | Phenotypes |
| HIFs | | |
| *HIF‑1α* | c.1156C>G (L386V) | Schizophrenia [1] |
|  | c.1744C>T (p.P582S) | Maximal oxygen consumption [2] |
|  | c.1742(p.A588T) | Renal cell carcinoma [3] |
| *HIF‑2α* | c.607A>C (p.N203H) | Congenital heart disorder [4] |
|  | c.824G>A (p.R275H) | Autism spectrum disorder [5] |
|  | c.1104G>A (p.M368I) | Pheochromocytoma [6] |
|  | c.1121T>A (p.F374Y) | Pheochromocytoma and polycythaemia with paraganglioma [6,7] |
|  | c.1234T>A (p.I412N) | Pheochromocytoma [6] |
|  | c.1235T>A (p.I412N) | Pheochromocytoma [6] |
|  | c.1586T>C (p.L529P) | Paraganglioma, polycythemia and somatostatinoma [8] |
|  | c.1588G>A (p.A530T) | Erythrocytosis and polycythaemia with paraganglioma [9-11] |
|  | c.1589C>A (p.A530E) | Pheochromocytoma [6] |
|  | c.1589C>T (p.A530V) | Polycythaemia with paraganglioma [10] |
|  | c.1591C>T (p.P531S) | Pheochromocytoma and polycythaemia with paraganglioma [10,12] |
|  | c.1591C>A (p.P531T) | Pheochromocytoma and paraganglioma [12] |
|  | c.1592C>T (p.P531L) | Pheochromocytoma and polycythaemia with paraganglioma [6,10,12] |
|  | c.1595A>G (p.Y532C) | Paraganglioma, polycythemia and somatostatinoma [6,8] |
|  | c.1597A>G (p.I533V) | Erythrocytosis [13] |
|  | c.1601C>T (p.P534L) | Erythrocytosis [14] |
|  | c.1604T>C (p.M535T) | Erythrocytosis [15] |
|  | c.1605G>A (p.M535I) | Erythrocytosis [16] |
|  | c.1603A>G (p.M535V) | Erythrocytosis [17] |
|  | c.1609G>A (p.G537R) | Erythrocytosis [18], pulmonary arterial hypertension [19] |
|  | c.1609G>T (p.G537W) | Erythrocytosis [18] |
|  | c.1615G>T (p.D539Y) | Polycythaemia with paraganglioma [10] |
|  | c.1617C>G (p.D539E) | Erythrocytosis [20] |
|  | c.1620C>G (p.F540L) | Erythrocytosis [15] |
|  | c.1625T>C (p.L542P) | Polycythaemia with paraganglioma [21] |
|  | c.2170G>T (p.G724W) | Congenital heart disease [4] |
| Dioxygenases - hydroxylases | | |
| *PHD1* | rs10680577 | Increased risk of hepatocellular carcinoma [22], lung cancer [23,24], gastric cancer [25], colorectal cancer [26]. |
|  | c.188T>A (p.S61R) | Pheochromocytoma/paraganglioma-polycythemia [27] |
| *PHD2* | c.12C>A(p.D4E) rs186996510 | High-altitude adaptation [28] |
|  | c.380G>C (p.S127C) rs12097901 | High-altitude adaptation [28] |
|  | c.471G>C (p.Q157H) | Erythrocytosis [29,30] |
|  | c.599C>A (P200Q) | Erythrocytosis [29] |
|  | c.606delG (p.M2021Ifs\*71) | Erythrocytosis [31] |
|  | c.609C>G (p.N203K) | Isolated erythrocytosis [30] |
|  | c.610G>A (p.K204E) | Erythrocytosis [32] |
|  | c.682G>C (p.A228S) | Pheochromocytoma/paraganglioma-polycythemia [27] |
|  | c.760G>C (p.D254H) | Erythrocytosis [29] |
|  | c.799G>A(p.E267K) | Pheochromocytoma [33] |
|  | c.835del14 (p.L279Tfs43\*) | Erythrocytosis [34] |
|  | c.840\_841insA (p.R281Tfs\*3) | Erythrocytosis [31] |
|  | c.853G>C (p.G285R) | Erythrocytosis [32] |
|  | c.872A>T (p.K291I) | Familial isolated erythrocytosis [30] |
|  | c.950C>G (p.P317R) | Familial erythrocytosis [35], cardiopulmonary [36] |
|  | c.1000T>C (p.W334R) | Familial erythrocytosis [37] |
|  | c.1001G>A (p.T334\*) | Erythrocytosis [38] |
|  | c.1010dup (p.V338Gfs\*18) | Erythrocytosis [32] |
|  | c.1112G>A (p.R371H) | Familial erythrocytosis [29,39] |
|  | c.1121A>G (p.H374R) | Familial erythrocytosis and recurrent paraganglioma [40]. |
|  | c.1129C>T (p. Q377\*) | Erythrocytosis [31] |
|  | c.1192C>T (p. R398\*) | Erythrocytosis [29] |
|  | c.1267A>G (p.K423E) | Isolated erythrocytosis [41] |
| *P4HA1* | c.1323\_1324insAG (p.R362Gfs\*9) | Congenital-onset disorder of connective tissue [42] |
|  | c.1553+2T>G (p.A418\_A434del) |
|  | c.1327A>G (p.K443\*) |
| *P4HA2* | c.419A>G (p.Q140R) | High myopia [43] |
|  | c.448A>G (p.I150V) |
|  | c.871G>A (p.E291K) |
|  | c.1327A>G (p.K443\*) |
|  | c.1349\_1350delGT (p.R451Gfs\*8) |
| *PAHX* | c.135-2A>G (p.Y46\_R82del) | Refsum disease [44] |
|  | c.164delT (p.L55fs\*12 ) | Refsum disease [45] |
|  | c.244C>G (p.R82G) | Nonsyndromic cleft lip and palate [46] |
|  | c.247A>T (p.N83Y) | Refsum disease [47] |
|  | c.258\_265del (p.E86fs\*26) | Refsum disease [47] |
|  | c.375\_376delGG (p.E126fs\*1) | Refsum disease [47] |
|  | c.412\_675del (p.E138\_W225del) | Refsum disease [48] |
|  | c.457delG (p.A152fs\*5) | Refsum disease [47] |
|  | c.497-2A>G (p.A166fs\*3) | Refsum disease [47] |
|  | c.517C>T (p.P173S) | Refsum disease [44] |
|  | c.524A>G (p.H175R) | Refsum disease [47] |
|  | c.526C>A (p.Q176K) | Refsum disease [44] |
|  | c.530A>G (p.N177G) | Refsum disease [44] |
|  | c.576\_577insGCC (p.192\_193insA) | Refsum disease [44] |
|  | c.577T>C (p.W193R) | Refsum disease [44] |
|  | c.589G>C (p.E197Q) | Refsum disease [44] |
|  | c.595A>T (p.I199F) | Refsum disease [44] |
|  | c.610G>A (p.G204S) | Refsum disease [49] |
|  | c.658C>T (p.H220Y) | Refsum disease [44] |
|  | c.678+2T4G (p.A166fs\*3) | Refsum disease [47] |
|  | c.678+5G4T (p.A166fs\*3) | Refsum disease [47] |
|  | c.679–1G4T (p.A166fs\*3) | Refsum disease [47] |
|  | c.683\_684insG (p.G228fs\*2) | Refsum disease [47] |
|  | c.703G>A (p.G235R) | Refsum disease [50] |
|  | c.734G>A (p.R245Q) | Refsum disease [44], nonsyndromic cleft lip and palate [46] |
|  | c.770T>C (p.F257S) | Refsum disease [44] |
|  | c.805A>C (N269H) | Refsum disease [45] |
|  | c.824G>A (p.R275Q) | Refsum disease [44] |
|  | c.823C>T (p.R275W) | Refsum disease [51] |
|  | c.829C>A (p.A277Q) | Refsum disease [52] |
|  | c.1014\_1015insATC (p.N337\_L338insH) | Nonsyndromic cleft lip and palate [46] |
| *FIH* | c.121C>G (p.P41A) | Colorectal cancer [53] |
| *TET1* | NR |  |
| *TET2* | c.1037T>C (p.L346P) | Myelodysplastic/myeloproliferative disease [54] |
|  | c.1652A>C (p.D551A) | Prostate cancer [55] |
|  | c.4115A>T (p.T1372I) | Myeloproliferative neoplasms [56] |
|  | c.3853\_3855del (p.S1285del) |
|  | p.Q891 |
|  | c.3629T>C(p.L1210P) |
|  | p.Arg544\* |
|  | splice donor c.3980 + 2G→T |
|  | p.D1858fs |
|  | c.3524G>A(p.G1275E) |
| *TET3* | c.1215delA (p.W406Gfs\*135) | Intellectual disability, developmental delay, autistic traits, hypotonia, growth abnormalities, facial dysmorphism and movement disorders [57] |
|  | c.2254C>T (p.R752C) |
|  | c.2552C>T (p.T851M) |
|  | c.2722G>T (p.V908L) |
|  | c.3215T>G (p.F1072C) |
|  | c.3226G>A (p.A1076T) |
|  | c.3265G>A (p.V1089M) |
|  | c.4977\_4983del (p.H1660Pfs\*52) |
|  | c.5030C>T (p.P1677L) |
|  | c.5083C>T (p.Q1695\*) |
| *FTO* | c.812A>C (p.H271P) | Developmental delay and dysmorphic facial features [58]. |
|  | c.947G>A (p.R316Q) | Growth retardation and multiple malformations {Boissel, 2009. |
|  | c.956C>T (p.S319F) | Developmental delay and growth retardation [59]. |
|  | c.965G>A (p.R322Q) | Growth retardation and multiple malformations [60]. |
|  | rs9939609 and rs8050136 | Obesity [61]. |
|  | rs9939609 | Type II diabetes [62] |
|  | rs7202116 | Obesity [63]. |
|  | rs9939609 | Metabolic syndrome including obesity, hypertension, dyslipidemia, and defective glucose tolerance [64]. |
|  | rs8050136 |
|  | rs1558902 |
|  | rs1421085 |
| Dioxygenases – lysine demethylases | | |
| *KDM3A* | c.1934C>A (p.P645Q) | Male infertility [65] |
|  | c.3956delA (p.G1211fs) | Male infertility [65] |
| *KDM3B* | c.4216C>T (p.R1406W) | Schizophrenia [66] |
|  | c.2624del (p.L875Rfs\*8) | Intellectual disability [67] |
|  | c.3422A>G (p.N1141S) | Wilms tumour and hyperpigmentation [68] |
|  | c.916\_917delAG | Hepatoblastoma, autism, intellectual disability, and abnormal pigmentation [68] |
|  | c.277G>T (p.E93\*) | Acute myeloid leukemia, mild intellectual disability, congenital hypothyroidism and congenital hip dysplasia [68] |
|  | c.3095A>T (p.D1032V) | Hodgkin lymphoma, feeding difficulties, intellectual disability, umbilical and inguinal hernia [69] |
|  | c.133C>T (p.R45\*) | Intellectual disability, facial dysmorphism and short stature [69] |
|  | c.277G>T (p.E93\*) |
|  | c.349T>C (p.W117R) |
|  | c.1007A>G (p.D336G) |
|  | c.2479C>T (p.Q827\*) |
|  | c.2827C>T (p.R943W) |
|  | c.2828G>A (p.R943Q) |
|  | c.3083G>A (p.R1028Q) |
|  | c.3095A>T (p.D132V) |
|  | c.4526T>C (p.L1509P) |
|  | c.4549C>T (p.R1517\*) |
|  | c.4631A>G (p.Y1544C) |
|  | c.1519G>A (p.E1731K) |
|  | c.5191G>A (p.E1731K) |
| *JMJD1C* | c.748\_749delTT (p.L250fs | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.488C>T (p.P163L) | Rett syndrome [71] |
|  | c.511G>A (p.V171I) | Intracranial germ cell tumour [72] |
|  | c.268A>G (p.N190D) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.860C>G (p.P287R) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.1636C>T (p.H546Y) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.1957C>T (p.P653S) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.2636\_2637insTT (p.S880P) | Intracranial germ cell tumour [72] |
|  | c.2822A>G (p.H941R) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.2830C>T (p.P944S) | Autism spectrum disorder [71] |
|  | c.3268A>G (p.K1060E) | Intracranial germ cell tumour [72] |
|  | c.3308A>G (p.N1103S) | Intellectual disability [71] |
|  | c.3349A>C (p.I1117L) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.3487A>G (p.I1163V) | Autism spectrum disorder [73] |
|  | c.3559A>G (p.T1187A) | Intellectual disability [71] |
|  | c.3743A>G (p.Q1248R) | Intellectual disability [71] |
|  | c.3982C>G (p.R1328G) | Autism spectrum disorder [71] |
|  | c.4286C>T (p.S1429L) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.2924G>C (p.K1462N) | Intracranial germ cell tumour [72] |
|  | c.4420T>C (p.S1474P) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
|  | c.4781T>C (p.I1594T) | Intracranial germ cell tumour [72] |
|  | c.6432A>G (p.I2144M) | Intracranial germ cell tumour [72] |
|  | c.6997A>G (p.T2333A) | Autism spectrum disorder [71] |
|  | c.7396C>T (H2466Y) | Congenital heart disease in patients with 22q11.2 deletion syndrome [70] |
| *KDM4C* | c.1186G>A (p.D396N) | Upper aerodigestive tract cancer [74] |
|  | c.3115G>A (p.V1039I) | Age at menarche [75] |
| *KDM5A* | c.2155C?G (p.R719G) | Intellectual disability [76]. |
|  | c.4522C>T (p.R1508W) | Congenital heart disease [77]. |
| *KDM5B* | c.4109T>G (p.L1370\*) | Intellectual disability, dyslexia, global developmental delay, facial dysmorphism [78] |
|  | c.2475-2A>G | Global developmental delay, intellectual disability, aggressive behaviour, facial dysmorphism [78] |
|  | c.895C>T (p.R299\*) |
|  | c.3906delC (p.N1302Kfs\*45) | Global developmental delay, hypospadias, facial dysmorphism [78] |
|  | c.622dupT (p.Y208Lfs\*5) |
| *KDM5C* | c.2T>C (p.M1T) | X-linked intellectual disability [79] |
|  | c.229G>A (p.A77T) | X-linked mental retardation [80] |
|  | c.260A>G 9p.D87G) | X-linked mental retardation [81] |
|  | c.994C>T (p.R332\*) | X-linked mental retardation [81] |
|  | c.1162G>C (p.A388P) | X-linked mental retardation [82] |
|  | c.1204G>T (p.D402Y) | X-linked mental retardation [82] |
|  | c.1270G>T (p.E424\*) | Intellectual disability [83] |
|  | c.1353C>G (p.S451R) | X-linked mental retardation [84] |
|  | c.1439C>T (p.P480L) | X-linked intellectual disability [85] |
|  | c.1510G>A (p.V504M) | X-linked mental retardation [80] |
|  | c.1660C>A (p.P554T) | X-linked mental retardation [86] |
|  | c.1919G>A (p.C640Y) | X-linked mental retardation [87] |
|  | c.1924T>C (p.F642L) | X-linked mental retardation [81] |
|  | c.2080C>T (p.R694\*) | X-linked mental retardation [82] |
|  | c.2092G>A (p.E698K) | X-linked mental retardation [82] |
|  | c.2152G>C (p.A718P) | Intellectual disability [88] |
|  | c.2172C>A (p.C724\*) | X-linked intellectual disability [89] |
|  | c.2191C>T (p.L731F) | X-linked mental retardation [82] |
|  | c.2248C>T (p.R750W) | X-linked mental retardation [81] |
|  | c.2252A>G (p.Y751C) | X-linked mental retardation [81] |
|  | c.2296C>T (p.R766W) | Autism spectrum disorder [90] |
|  | c.2908C>T (p.Q970\*) | Intellectual disability [91] |
|  | c.3285C>A (p.C1095\*) | Intellectual disability [81] |
|  | c.3864G>A (p.W1288\*) | X-linked mental retardation [82] |
|  | IVS11ds+5G>A | X-linked mental retardation [80] |
|  | IVS5ds+2T>C | Intellectual disability [91] |
|  | c.1600delT(p.W534Gfs\*15) | Intellectual disability [91] |
|  | c.2047delG (p.A683Pfs\*81) | Intellectual disability [81] |
|  | c.3223delG (p.V1075Yfs\*2) | X-linked intellectual disability [92] |
|  | c.4441\_4442delAG (p.R1481Gfs\*9) | X-linked mental retardation [80] |
|  | c.202\_203insC (p.68fs\*7) | X-linked mental retardation [82] |
|  | c.1296dup (p.E433\*) | Intellectual disability [88] |
|  | c.3258\_3259insC (p.K1087fs\*43) | X-linked mental retardation [86] |
|  | 0.4 Mb microdeletion at Xp11.22 | Intellectual disability [93] |
| *KDM6A* | c.171dupT (p.G58Wfs\*7) | Kabuki syndrome [94] |
|  | c.190G>T (p.E64\*) | Kabuki syndrome [94] |
|  | c.335−1G>T | Kabuki syndrome [95] |
|  | c.342C>T (p.R172\*) | Kabuki syndrome [96,97] |
|  | c.443+5G>C | Kabuki syndrome [94] |
|  | c.563A>G (p.K188R) | Kabuki syndrome [96] |
|  | c.619+6T>C | Kabuki syndrome [94] |
|  | c.620−2A>G | Kabuki syndrome [94] |
|  | c.752G>A (p.W251\*) | Kabuki syndrome [98] |
|  | c.1555C>T (p.R519\*) | Kabuki syndrome [99] |
|  | c.1834C>T (p.R612\*) | Renal cancer [100] |
|  | c.1846\_1849delACTC (p.T616Yfs\*8) | Kabuki syndrome [97] |
|  | c.1909\_1912delTCTA (p.S637Tfs\*53) | Kabuki syndrome [101] |
|  | c.2226\_2227dupCA (p.S743Tfs\*13) | Kabuki syndrome [94] |
|  | c.2515\_2518del (p.N839Vfs\*27) | Kabuki syndrome [102] |
|  | c.2729A>G (p.N910S) | Kabuki syndrome [94] |
|  | c.2832+1G>A | Kabuki syndrome [94] |
|  | c.2839A>T (p.D980V) | Kabuki syndrome [97] |
|  | c.3073A>G (p.S1025G) | Kabuki syndrome [94] |
|  | c.3109C>T (p.Q1037\*) | Kabuki syndrome [94] |
|  | c.3284+3\_3284+6delAAGT (p.N1070\_K1094del) | Kabuki syndrome [97] |
|  | c.3354\_3356delTCT (p.L1119del) | Kabuki syndrome [101] |
|  | c.3717G>A (p.W1239\*) | Kabuki syndrome [101] |
|  | c.3763C>T (p.R1255W) | Kabuki syndrome [94] |
|  | c.3835C>T (p.R1279\*) | Kabuki syndrome [103] |
|  | c.4051C>T (p.R1351\*) | Kabuki syndrome [99] |
|  | c.3284+1G>T | Kabuki syndrome [96] |
|  | c.3548+2T>C | Kabuki syndrome [96] |
|  | Exon 6 deletion | Kabuki syndrome [96] |
|  | site  c.3878+3\_3878+6delAAGT (  c.3878+3\_3878+6delAAGT | Kabuki syndrome [96] |
|  | c.3501delT (p.F1167Lfs\*11) | Kabuki syndrome [96] |
|  | c.3736+2T>C | Kabuki syndrome [98] |
|  | c. 3835C>T (p.R1279\*) | Biliary atresia with Kabuki syndrome-like features [104] |
|  | c.3876\_3878delTAA+1delG | Kabuki syndrome [105] |
| *KDM6B* | c.2661C>T (p.P888S) | Intellectual disability [76] |
|  | IVS9ds+5G>T | Intellectual disability, brachydactyly and dysmorphism [106] |
| *KDM7B* | c.529A>T (p.K177\*) | X-linked mental retardation with cleft lip/palate [107] |
|  | c.631C>T (p.R211\*) | X-linked mental retardation with cleft lip/palate [108] |
|  | c.836T>C (p.F279S) | X-linked mental retardation with cleft lip/palate [109] |
|  | p.S969del | Autism and Asperger syndrome [110] |
|  | c.943\_954del | X-linked mental retardation with cleft lip/palate [108] |
|  | g.218-254 kb covering KDM7B | Autism spectrum disorder, intellectual disability, cleft palate and Aarskog syndrome [111] |
|  | g.236,505 bp | Intellectual disability [91] |

NR, not reported.

1. Gulsuner, S.; Walsh, T.; Watts, A.C.; Lee, M.K.; Thornton, A.M.; Casadei, S.; Rippey, C.; Shahin, H.; Consortium on the Genetics of, S.; Group, P.S.*, et al.* Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. *Cell* **2013**, *154*, 518-529.

2. Prior, S.J.; Hagberg, J.M.; Phares, D.A.; Brown, M.D.; Fairfull, L.; Ferrell, R.E.; Roth, S.M. Sequence variation in hypoxia-inducible factor 1alpha (hif1a): Association with maximal oxygen consumption. *Physiol Genomics* **2003**, *15*, 20-26.

3. Ollerenshaw, M.; Page, T.; Hammonds, J.; Demaine, A. Polymorphisms in the hypoxia inducible factor-1alpha gene (hif1a) are associated with the renal cell carcinoma phenotype. *Cancer Genet Cytogenet* **2004**, *153*, 122-126.

4. Pan, H.; Chen, Q.; Qi, S.; Li, T.; Liu, B.; Liu, S.; Ma, X.; Wang, B. Mutations in epas1 in congenital heart disease in tibetans. *Biosci Rep* **2018**, *38*.

5. An, J.Y.; Cristino, A.S.; Zhao, Q.; Edson, J.; Williams, S.M.; Ravine, D.; Wray, J.; Marshall, V.M.; Hunt, A.; Whitehouse, A.J.*, et al.* Towards a molecular characterization of autism spectrum disorders: An exome sequencing and systems approach. *Transl Psychiatry* **2014**, *4*, e394.

6. Welander, J.; Andreasson, A.; Brauckhoff, M.; Backdahl, M.; Larsson, C.; Gimm, O.; Soderkvist, P. Frequent epas1/hif2alpha exons 9 and 12 mutations in non-familial pheochromocytoma. *Endocr Relat Cancer* **2014**, *21*, 495-504.

7. Lorenzo, F.R.; Yang, C.; Ng Tang Fui, M.; Vankayalapati, H.; Zhuang, Z.; Huynh, T.; Grossmann, M.; Pacak, K.; Prchal, J.T. A novel epas1/hif2a germline mutation in a congenital polycythemia with paraganglioma. *J Mol Med (Berl)* **2013**, *91*, 507-512.

8. Yang, C.; Sun, M.G.; Matro, J.; Huynh, T.T.; Rahimpour, S.; Prchal, J.T.; Lechan, R.; Lonser, R.; Pacak, K.; Zhuang, Z. Novel hif2a mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. *Blood* **2013**, *121*, 2563-2566.

9. Yang, C.; Hong, C.S.; Prchal, J.T.; Balint, M.T.; Pacak, K.; Zhuang, Z. Somatic mosaicism of epas1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. *Hum Genome Var* **2015**, *2*, 15053.

10. Comino-Mendez, I.; de Cubas, A.A.; Bernal, C.; Alvarez-Escola, C.; Sanchez-Malo, C.; Ramirez-Tortosa, C.L.; Pedrinaci, S.; Rapizzi, E.; Ercolino, T.; Bernini, G.*, et al.* Tumoral epas1 (hif2a) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. *Hum Mol Genet* **2013**, *22*, 2169-2176.

11. Zhuang, Z.; Yang, C.; Lorenzo, F.; Merino, M.; Fojo, T.; Kebebew, E.; Popovic, V.; Stratakis, C.A.; Prchal, J.T.; Pacak, K. Somatic hif2a gain-of-function mutations in paraganglioma with polycythemia. *N Engl J Med* **2012**, *367*, 922-930.

12. Toledo, R.A.; Qin, Y.; Srikantan, S.; Morales, N.P.; Li, Q.; Deng, Y.; Kim, S.W.; Pereira, M.A.; Toledo, S.P.; Su, X.*, et al.* In vivo and in vitro oncogenic effects of hif2a mutations in pheochromocytomas and paragangliomas. *Endocr Relat Cancer* **2013**, *20*, 349-359.

13. Perrotta, S.; Stiehl, D.P.; Punzo, F.; Scianguetta, S.; Borriello, A.; Bencivenga, D.; Casale, M.; Nobili, B.; Fasoli, S.; Balduzzi, A.*, et al.* Congenital erythrocytosis associated with gain-of-function hif2a gene mutations and erythropoietin levels in the normal range. *Haematologica* **2013**, *98*, 1624-1632.

14. Furlow, P.W.; Percy, M.J.; Sutherland, S.; Bierl, C.; McMullin, M.F.; Master, S.R.; Lappin, T.R.; Lee, F.S. Erythrocytosis-associated hif-2alpha mutations demonstrate a critical role for residues c-terminal to the hydroxylacceptor proline. *J Biol Chem* **2009**, *284*, 9050-9058.

15. Percy, M.J.; Chung, Y.J.; Harrison, C.; Mercieca, J.; Hoffbrand, A.V.; Dinardo, C.L.; Santos, P.C.; Fonseca, G.H.; Gualandro, S.F.; Pereira, A.C.*, et al.* Two new mutations in the hif2a gene associated with erythrocytosis. *Am J Hematol* **2012**, *87*, 439-442.

16. Martini, M.; Teofili, L.; Cenci, T.; Giona, F.; Torti, L.; Rea, M.; Foa, R.; Leone, G.; Larocca, L.M. A novel heterozygous hif2am535i mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. *Haematologica* **2008**, *93*, 1068-1071.

17. Percy, M.J.; Beer, P.A.; Campbell, G.; Dekker, A.W.; Green, A.R.; Oscier, D.; Rainey, M.G.; van Wijk, R.; Wood, M.; Lappin, T.R.*, et al.* Novel exon 12 mutations in the hif2a gene associated with erythrocytosis. *Blood* **2008**, *111*, 5400-5402.

18. Percy, M.J.; Furlow, P.W.; Lucas, G.S.; Li, X.; Lappin, T.R.; McMullin, M.F.; Lee, F.S. A gain-of-function mutation in the hif2a gene in familial erythrocytosis. *N Engl J Med* **2008**, *358*, 162-168.

19. Gale, D.P.; Harten, S.K.; Reid, C.D.; Tuddenham, E.G.; Maxwell, P.H. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating hif2 alpha mutation. *Blood* **2008**, *112*, 919-921.

20. van Wijk, R.; Sutherland, S.; Van Wesel, A.C.; Huizinga, E.G.; Percy, M.J.; Bierings, M.; Lee, F.S. Erythrocytosis associated with a novel missense mutation in the hif2a gene. *Haematologica* **2010**, *95*, 829-832.

21. Buffet, A.; Smati, S.; Mansuy, L.; Menara, M.; Lebras, M.; Heymann, M.F.; Simian, C.; Favier, J.; Murat, A.; Cariou, B.*, et al.* Mosaicism in hif2a-related polycythemia-paraganglioma syndrome. *J Clin Endocrinol Metab* **2014**, *99*, E369-373.

22. Zhu, Z.; Gao, X.; He, Y.; Zhao, H.; Yu, Q.; Jiang, D.; Zhang, P.; Ma, X.; Huang, H.; Dong, D.*, et al.* An insertion/deletion polymorphism within rert-lncrna modulates hepatocellular carcinoma risk. *Cancer Res* **2012**, *72*, 6163-6172.

23. Che, J.; Jiang, D.; Zheng, Y.; Zhu, B.; Zhang, P.; Lu, D.; Zhang, J.; Xiao, J.; Wang, J.; Gao, Y.*, et al.* Polymorphism in phd1 gene and risk of non-small cell lung cancer in a chinese population. *Tumour Biol* **2014**, *35*, 8921-8925.

24. Zhu, J.; Luo, J.Z.; Li, C.B. Correlations of an insertion/deletion polymorphism (rs10680577) in the rert-lncrna with the susceptibility, clinicopathological features, and prognosis of lung cancer. *Biochem Genet* **2019**, *57*, 147-158.

25. Wang, J.; Zhang, J.; Zhou, C.; Chen, L.; Yu, Q. An insertion/deletion polymorphism within the proximal promoter of egln2 is associated with susceptibility for gastric cancer in the chinese population. *Genet Test Mol Biomarkers* **2014**, *18*, 269-273.

26. Li, C.; Feng, L.; Niu, L.; Teng Li, T.; Zhang, B.; Wan, H.; Zhu, Z.; Liu, H.; Wang, K.; Fu, H.*, et al.* An insertion/deletion polymorphism within the promoter of egln2 is associated with susceptibility to colorectal cancer. *Int J Biol Markers* **2017**, *32*, e274-e277.

27. Yang, C.; Zhuang, Z.; Fliedner, S.M.; Shankavaram, U.; Sun, M.G.; Bullova, P.; Zhu, R.; Elkahloun, A.G.; Kourlas, P.J.; Merino, M.*, et al.* Germ-line phd1 and phd2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. *J Mol Med (Berl)* **2015**, *93*, 93-104.

28. Xiang, K.; Ouzhuluobu; Peng, Y.; Yang, Z.; Zhang, X.; Cui, C.; Zhang, H.; Li, M.; Zhang, Y.; Bianba*, et al.* Identification of a tibetan-specific mutation in the hypoxic gene egln1 and its contribution to high-altitude adaptation. *Mol Biol Evol* **2013**, *30*, 1889-1898.

29. Ladroue, C.; Hoogewijs, D.; Gad, S.; Carcenac, R.; Storti, F.; Barrois, M.; Gimenez-Roqueplo, A.P.; Leporrier, M.; Casadevall, N.; Hermine, O.*, et al.* Distinct deregulation of the hypoxia inducible factor by phd2 mutants identified in germline DNA of patients with polycythemia. *Haematologica* **2012**, *97*, 9-14.

30. Albiero, E.; Ruggeri, M.; Fortuna, S.; Bernardi, M.; Finotto, S.; Madeo, D.; Rodeghiero, F. Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel egln1 germ-line mutation. *Br J Haematol* **2011**, *153*, 405-408.

31. Al-Sheikh, M.; Moradkhani, K.; Lopez, M.; Wajcman, H.; Prehu, C. Disturbance in the hif-1alpha pathway associated with erythrocytosis: Further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (phd2) gene. *Blood Cells Mol Dis* **2008**, *40*, 160-165.

32. Bento, C.; Percy, M.J.; Gardie, B.; Maia, T.M.; van Wijk, R.; Perrotta, S.; Della Ragione, F.; Almeida, H.; Rossi, C.; Girodon, F.*, et al.* Genetic basis of congenital erythrocytosis: Mutation update and online databases. *Hum Mutat* **2014**, *35*, 15-26.

33. Welander, J.; Andreasson, A.; Juhlin, C.C.; Wiseman, R.W.; Backdahl, M.; Hoog, A.; Larsson, C.; Gimm, O.; Soderkvist, P. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab* **2014**, *99*, E1352-1360.

34. Jang, J.H.; Seo, J.Y.; Jang, J.; Jung, C.W.; Lee, K.O.; Kim, S.H.; Kim, H.J. Hereditary gene mutations in korean patients with isolated erythrocytosis. *Ann Hematol* **2014**, *93*, 931-935.

35. Percy, M.J.; Zhao, Q.; Flores, A.; Harrison, C.; Lappin, T.R.; Maxwell, P.H.; McMullin, M.F.; Lee, F.S. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. *Proc Natl Acad Sci U S A* **2006**, *103*, 654-659.

36. Talbot, N.P.; Smith, T.G.; Balanos, G.M.; Dorrington, K.L.; Maxwell, P.H.; Robbins, P.A. Cardiopulmonary phenotype associated with human phd2 mutation. *Physiol Rep* **2017**, *5*.

37. Bento, C.; Almeida, H.; Maia, T.M.; Relvas, L.; Oliveira, A.C.; Rossi, C.; Girodon, F.; Fernandez-Lago, C.; Aguado-Diaz, A.; Fraga, C.*, et al.* Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (where is/are the missing gene(s)?). *Eur J Haematol* **2013**, *91*, 361-368.

38. Wilson, R.; Syed, N.; Shah, P. Erythrocytosis due to phd2 mutations: A review of clinical presentation, diagnosis, and genetics. *Case Rep Hematol* **2016**, *2016*, 6373706.

39. Percy, M.J.; Furlow, P.W.; Beer, P.A.; Lappin, T.R.; McMullin, M.F.; Lee, F.S. A novel erythrocytosis-associated phd2 mutation suggests the location of a hif binding groove. *Blood* **2007**, *110*, 2193-2196.

40. Ladroue, C.; Carcenac, R.; Leporrier, M.; Gad, S.; Le Hello, C.; Galateau-Salle, F.; Feunteun, J.; Pouyssegur, J.; Richard, S.; Gardie, B. Phd2 mutation and congenital erythrocytosis with paraganglioma. *N Engl J Med* **2008**, *359*, 2685-2692.

41. Albiero, E.; Ruggeri, M.; Fortuna, S.; Finotto, S.; Bernardi, M.; Madeo, D.; Rodeghiero, F. Isolated erythrocytosis: Study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (phd2) gene. *Haematologica* **2012**, *97*, 123-127.

42. Zou, Y.; Donkervoort, S.; Salo, A.M.; Foley, A.R.; Barnes, A.M.; Hu, Y.; Makareeva, E.; Leach, M.E.; Mohassel, P.; Dastgir, J.*, et al.* P4ha1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye. *Hum Mol Genet* **2017**, *26*, 2207-2217.

43. Guo, H.; Tong, P.; Liu, Y.; Xia, L.; Wang, T.; Tian, Q.; Li, Y.; Hu, Y.; Zheng, Y.; Jin, X.*, et al.* Mutations of p4ha2 encoding prolyl 4-hydroxylase 2 are associated with nonsyndromic high myopia. *Genet Med* **2015**, *17*, 300-306.

44. Jansen, G.A.; Hogenhout, E.M.; Ferdinandusse, S.; Waterham, H.R.; Ofman, R.; Jakobs, C.; Skjeldal, O.H.; Wanders, R.J. Human phytanoyl-coa hydroxylase: Resolution of the gene structure and the molecular basis of refsum's disease. *Hum Mol Genet* **2000**, *9*, 1195-1200.

45. Jansen, G.A.; Ofman, R.; Ferdinandusse, S.; Ijlst, L.; Muijsers, A.O.; Skjeldal, O.H.; Stokke, O.; Jakobs, C.; Besley, G.T.; Wraith, J.E.*, et al.* Refsum disease is caused by mutations in the phytanoyl-coa hydroxylase gene. *Nat Genet* **1997**, *17*, 190-193.

46. Aylward, A.; Cai, Y.; Lee, A.; Blue, E.; Rabinowitz, D.; Haddad, J., Jr.; University of Washington Center for Mendelian, G. Using whole exome sequencing to identify candidate genes with rare variants in nonsyndromic cleft lip and palate. *Genet Epidemiol* **2016**, *40*, 432-441.

47. Jansen, G.A.; Waterham, H.R.; Wanders, R.J. Molecular basis of refsum disease: Sequence variations in phytanoyl-coa hydroxylase (phyh) and the pts2 receptor (pex7). *Hum Mutat* **2004**, *23*, 209-218.

48. Chahal, A.; Khan, M.; Pai, S.G.; Barbosa, E.; Singh, I. Restoration of phytanic acid oxidation in refsum disease fibroblasts from patients with mutations in the phytanoyl-coa hydroxylase gene. *FEBS Lett* **1998**, *429*, 119-122.

49. Jansen, G.A.; Ferdinandusse, S.; Skjeldal, O.H.; Stokke, O.; de Groot, C.J.; Jakobs, C.; Wanders, R.J. Molecular basis of refsum disease: Identification of new mutations in the phytanoyl-coa hydroxylase cdna. *J Inherit Metab Dis* **1998**, *21*, 288-291.

50. Zhao, L.; Wang, F.; Wang, H.; Li, Y.; Alexander, S.; Wang, K.; Willoughby, C.E.; Zaneveld, J.E.; Jiang, L.; Soens, Z.T.*, et al.* Next-generation sequencing-based molecular diagnosis of 82 retinitis pigmentosa probands from northern ireland. *Hum Genet* **2015**, *134*, 217-230.

51. Mihalik, S.J.; Morrell, J.C.; Kim, D.; Sacksteder, K.A.; Watkins, P.A.; Gould, S.J. Identification of pahx, a refsum disease gene. *Nat Genet* **1997**, *17*, 185-189.

52. Kohlschutter, A.; Santer, R.; Lukacs, Z.; Altenburg, C.; Kemper, M.J.; Ruther, K. A child with night blindness: Preventing serious symptoms of refsum disease. *J Child Neurol* **2012**, *27*, 654-656.

53. Webb, E.L.; Rudd, M.F.; Sellick, G.S.; El Galta, R.; Bethke, L.; Wood, W.; Fletcher, O.; Penegar, S.; Withey, L.; Qureshi, M.*, et al.* Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous snps in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. *Hum Mol Genet* **2006**, *15*, 3263-3271.

54. Ismael, O.; Shimada, A.; Hama, A.; Elshazley, M.; Muramatsu, H.; Goto, A.; Sakaguchi, H.; Tanaka, M.; Takahashi, Y.; Yinyan, X.*, et al.* De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics. *Br J Haematol* **2012**, *158*, 129-137.

55. Nickerson, M.L.; Im, K.M.; Misner, K.J.; Tan, W.; Lou, H.; Gold, B.; Wells, D.W.; Bravo, H.C.; Fredrikson, K.M.; Harkins, T.T.*, et al.* Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. *Hum Mutat* **2013**, *34*, 1231-1241.

56. Schaub, F.X.; Looser, R.; Li, S.; Hao-Shen, H.; Lehmann, T.; Tichelli, A.; Skoda, R.C. Clonal analysis of tet2 and jak2 mutations suggests that tet2 can be a late event in the progression of myeloproliferative neoplasms. *Blood* **2010**, *115*, 2003-2007.

57. Beck, D.B.; Petracovici, A.; He, C.; Moore, H.W.; Louie, R.J.; Ansar, M.; Douzgou, S.; Sithambaram, S.; Cottrell, T.; Santos-Cortez, R.L.P.*, et al.* Delineation of a human mendelian disorder of the DNA demethylation machinery: Tet3 deficiency. *Am J Hum Genet* **2020**, *106*, 234-245.

58. Caglayan, A.O.; Tuysuz, B.; Coskun, S.; Quon, J.; Harmanci, A.S.; Baranoski, J.F.; Baran, B.; Erson-Omay, E.Z.; Henegariu, O.; Mane, S.M.*, et al.* A patient with a novel homozygous missense mutation in fto and concomitant nonsense mutation in cetp. *J Hum Genet* **2016**, *61*, 395-403.

59. Daoud, H.; Zhang, D.; McMurray, F.; Yu, A.; Luco, S.M.; Vanstone, J.; Jarinova, O.; Carson, N.; Wickens, J.; Shishodia, S.*, et al.* Identification of a pathogenic fto mutation by next-generation sequencing in a newborn with growth retardation and developmental delay. *J Med Genet* **2016**, *53*, 200-207.

60. Rohena, L.; Lawson, M.; Guzman, E.; Ganapathi, M.; Cho, M.T.; Haverfield, E.; Anyane-Yeboa, K. Fto variant associated with malformation syndrome. *Am J Med Genet A* **2016**, *170A*, 1023-1028.

61. Song, Y.; You, N.C.; Hsu, Y.H.; Howard, B.V.; Langer, R.D.; Manson, J.E.; Nathan, L.; Niu, T.; L, F.T.; Liu, S. Fto polymorphisms are associated with obesity but not diabetes risk in postmenopausal women. *Obesity (Silver Spring)* **2008**, *16*, 2472-2480.

62. Frayling, T.M.; Timpson, N.J.; Weedon, M.N.; Zeggini, E.; Freathy, R.M.; Lindgren, C.M.; Perry, J.R.; Elliott, K.S.; Lango, H.; Rayner, N.W.*, et al.* A common variant in the fto gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **2007**, *316*, 889-894.

63. Yang, J.; Loos, R.J.; Powell, J.E.; Medland, S.E.; Speliotes, E.K.; Chasman, D.I.; Rose, L.M.; Thorleifsson, G.; Steinthorsdottir, V.; Magi, R.*, et al.* Fto genotype is associated with phenotypic variability of body mass index. *Nature* **2012**, *490*, 267-272.

64. Hotta, K.; Kitamoto, T.; Kitamoto, A.; Mizusawa, S.; Matsuo, T.; Nakata, Y.; Kamohara, S.; Miyatake, N.; Kotani, K.; Komatsu, R.*, et al.* Association of variations in the fto, scg3 and mtmr9 genes with metabolic syndrome in a japanese population. *J Hum Genet* **2011**, *56*, 647-651.

65. Hojati, Z.; Soleimanpour, E.; Javadirad, S.M.; Nasr-Esfahani, M.H. Identification of two novel mutations in kdm3a regulatory gene in iranian infertile males. *Iran Biomed J* **2019**, *23*, 220-227.

66. Guipponi, M.; Santoni, F.A.; Setola, V.; Gehrig, C.; Rotharmel, M.; Cuenca, M.; Guillin, O.; Dikeos, D.; Georgantopoulos, G.; Papadimitriou, G.*, et al.* Exome sequencing in 53 sporadic cases of schizophrenia identifies 18 putative candidate genes. *PLoS One* **2014**, *9*, e112745.

67. Deciphering Developmental Disorders, S. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* **2017**, *542*, 433-438.

68. Mahamdallie, S.; Yost, S.; Poyastro-Pearson, E.; Holt, E.; Zachariou, A.; Seal, S.; Elliott, A.; Clarke, M.; Warren-Perry, M.; Hanks, S.*, et al.* Identification of new wilms tumour predisposition genes: An exome sequencing study. *Lancet Child Adolesc Health* **2019**, *3*, 322-331.

69. Diets, I.J.; van der Donk, R.; Baltrunaite, K.; Waanders, E.; Reijnders, M.R.F.; Dingemans, A.J.M.; Pfundt, R.; Vulto-van Silfhout, A.T.; Wiel, L.; Gilissen, C.*, et al.* De novo and inherited pathogenic variants in kdm3b cause intellectual disability, short stature, and facial dysmorphism. *Am J Hum Genet* **2019**, *104*, 758-766.

70. Guo, T.; Chung, J.H.; Wang, T.; McDonald-McGinn, D.M.; Kates, W.R.; Hawula, W.; Coleman, K.; Zackai, E.; Emanuel, B.S.; Morrow, B.E. Histone modifier genes alter conotruncal heart phenotypes in 22q11.2 deletion syndrome. *Am J Hum Genet* **2015**, *97*, 869-877.

71. Saez, M.A.; Fernandez-Rodriguez, J.; Moutinho, C.; Sanchez-Mut, J.V.; Gomez, A.; Vidal, E.; Petazzi, P.; Szczesna, K.; Lopez-Serra, P.; Lucariello, M.*, et al.* Mutations in jmjd1c are involved in rett syndrome and intellectual disability. *Genet Med* **2016**, *18*, 378-385.

72. Wang, L.; Yamaguchi, S.; Burstein, M.D.; Terashima, K.; Chang, K.; Ng, H.K.; Nakamura, H.; He, Z.; Doddapaneni, H.; Lewis, L.*, et al.* Novel somatic and germline mutations in intracranial germ cell tumours. *Nature* **2014**, *511*, 241-245.

73. Neale, B.M.; Kou, Y.; Liu, L.; Ma'ayan, A.; Samocha, K.E.; Sabo, A.; Lin, C.F.; Stevens, C.; Wang, L.S.; Makarov, V.*, et al.* Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* **2012**, *485*, 242-245.

74. Canova, C.; Hashibe, M.; Simonato, L.; Nelis, M.; Metspalu, A.; Lagiou, P.; Trichopoulos, D.; Ahrens, W.; Pigeot, I.; Merletti, F.*, et al.* Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 european countries: The arcage project. *Cancer Res* **2009**, *69*, 2956-2965.

75. Perry, J.R.; Day, F.; Elks, C.E.; Sulem, P.; Thompson, D.J.; Ferreira, T.; He, C.; Chasman, D.I.; Esko, T.; Thorleifsson, G.*, et al.* Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* **2014**, *514*, 92-97.

76. Najmabadi, H.; Hu, H.; Garshasbi, M.; Zemojtel, T.; Abedini, S.S.; Chen, W.; Hosseini, M.; Behjati, F.; Haas, S.; Jamali, P.*, et al.* Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **2011**, *478*, 57-63.

77. Zaidi, S.; Choi, M.; Wakimoto, H.; Ma, L.; Jiang, J.; Overton, J.D.; Romano-Adesman, A.; Bjornson, R.D.; Breitbart, R.E.; Brown, K.K.*, et al.* De novo mutations in histone-modifying genes in congenital heart disease. *Nature* **2013**, *498*, 220-223.

78. Faundes, V.; Newman, W.G.; Bernardini, L.; Canham, N.; Clayton-Smith, J.; Dallapiccola, B.; Davies, S.J.; Demos, M.K.; Goldman, A.; Gill, H.*, et al.* Histone lysine methylases and demethylases in the landscape of human developmental disorders. *Am J Hum Genet* **2018**, *102*, 175-187.

79. Ounap, K.; Puusepp-Benazzouz, H.; Peters, M.; Vaher, U.; Rein, R.; Proos, A.; Field, M.; Reimand, T. A novel c.2t > c mutation of the kdm5c/jarid1c gene in one large family with x-linked intellectual disability. *Eur J Med Genet* **2012**, *55*, 178-184.

80. Abidi, F.E.; Holloway, L.; Moore, C.A.; Weaver, D.D.; Simensen, R.J.; Stevenson, R.E.; Rogers, R.C.; Schwartz, C.E. Mutations in jarid1c are associated with x-linked mental retardation, short stature and hyperreflexia. *J Med Genet* **2008**, *45*, 787-793.

81. Tzschach, A.; Lenzner, S.; Moser, B.; Reinhardt, R.; Chelly, J.; Fryns, J.P.; Kleefstra, T.; Raynaud, M.; Turner, G.; Ropers, H.H.*, et al.* Novel jarid1c/smcx mutations in patients with x-linked mental retardation. *Hum Mutat* **2006**, *27*, 389.

82. Jensen, L.R.; Amende, M.; Gurok, U.; Moser, B.; Gimmel, V.; Tzschach, A.; Janecke, A.R.; Tariverdian, G.; Chelly, J.; Fryns, J.P.*, et al.* Mutations in the jarid1c gene, which is involved in transcriptional regulation and chromatin remodeling, cause x-linked mental retardation. *Am J Hum Genet* **2005**, *76*, 227-236.

83. Grozeva, D.; Carss, K.; Spasic-Boskovic, O.; Tejada, M.I.; Gecz, J.; Shaw, M.; Corbett, M.; Haan, E.; Thompson, E.; Friend, K.*, et al.* Targeted next-generation sequencing analysis of 1,000 individuals with intellectual disability. *Hum Mutat* **2015**, *36*, 1197-1204.

84. Santos, C.; Rodriguez-Revenga, L.; Madrigal, I.; Badenas, C.; Pineda, M.; Mila, M. A novel mutation in jarid1c gene associated with mental retardation. *Eur J Hum Genet* **2006**, *14*, 583-586.

85. Grafodatskaya, D.; Chung, B.H.; Butcher, D.T.; Turinsky, A.L.; Goodman, S.J.; Choufani, S.; Chen, Y.A.; Lou, Y.; Zhao, C.; Rajendram, R.*, et al.* Multilocus loss of DNA methylation in individuals with mutations in the histone h3 lysine 4 demethylase kdm5c. *BMC Med Genomics* **2013**, *6*, 1.

86. Rujirabanjerd, S.; Nelson, J.; Tarpey, P.S.; Hackett, A.; Edkins, S.; Raymond, F.L.; Schwartz, C.E.; Turner, G.; Iwase, S.; Shi, Y.*, et al.* Identification and characterization of two novel jarid1c mutations: Suggestion of an emerging genotype-phenotype correlation. *Eur J Hum Genet* **2010**, *18*, 330-335.

87. Vissers, L.E.; de Ligt, J.; Gilissen, C.; Janssen, I.; Steehouwer, M.; de Vries, P.; van Lier, B.; Arts, P.; Wieskamp, N.; del Rosario, M.*, et al.* A de novo paradigm for mental retardation. *Nat Genet* **2010**, *42*, 1109-1112.

88. Redin, C.; Gerard, B.; Lauer, J.; Herenger, Y.; Muller, J.; Quartier, A.; Masurel-Paulet, A.; Willems, M.; Lesca, G.; El-Chehadeh, S.*, et al.* Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. *J Med Genet* **2014**, *51*, 724-736.

89. Santos-Reboucas, C.B.; Fintelman-Rodrigues, N.; Jensen, L.R.; Kuss, A.W.; Ribeiro, M.G.; Campos, M., Jr.; Santos, J.M.; Pimentel, M.M. A novel nonsense mutation in kdm5c/jarid1c gene causing intellectual disability, short stature and speech delay. *Neurosci Lett* **2011**, *498*, 67-71.

90. Adegbola, A.; Gao, H.; Sommer, S.; Browning, M. A novel mutation in jarid1c/smcx in a patient with autism spectrum disorder (asd). *Am J Med Genet A* **2008**, *146A*, 505-511.

91. Hu, H.; Haas, S.A.; Chelly, J.; Van Esch, H.; Raynaud, M.; de Brouwer, A.P.; Weinert, S.; Froyen, G.; Frints, S.G.; Laumonnier, F.*, et al.* X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. *Mol Psychiatry* **2016**, *21*, 133-148.

92. Brookes, E.; Laurent, B.; Ounap, K.; Carroll, R.; Moeschler, J.B.; Field, M.; Schwartz, C.E.; Gecz, J.; Shi, Y. Mutations in the intellectual disability gene kdm5c reduce protein stability and demethylase activity. *Hum Mol Genet* **2015**, *24*, 2861-2872.

93. Fieremans, N.; Van Esch, H.; de Ravel, T.; Van Driessche, J.; Belet, S.; Bauters, M.; Froyen, G. Microdeletion of the escape genes kdm5c and iqsec2 in a girl with severe intellectual disability and autistic features. *Eur J Med Genet* **2015**, *58*, 324-327.

94. Bogershausen, N.; Gatinois, V.; Riehmer, V.; Kayserili, H.; Becker, J.; Thoenes, M.; Simsek-Kiper, P.O.; Barat-Houari, M.; Elcioglu, N.H.; Wieczorek, D.*, et al.* Mutation update for kabuki syndrome genes kmt2d and kdm6a and further delineation of x-linked kabuki syndrome subtype 2. *Hum Mutat* **2016**, *37*, 847-864.

95. Guo, Z.; Liu, F.; Li, H.J. Novel kdm6a splice-site mutation in kabuki syndrome with congenital hydrocephalus: A case report. *BMC Med Genet* **2018**, *19*, 206.

96. Banka, S.; Lederer, D.; Benoit, V.; Jenkins, E.; Howard, E.; Bunstone, S.; Kerr, B.; McKee, S.; Lloyd, I.C.; Shears, D.*, et al.* Novel kdm6a (utx) mutations and a clinical and molecular review of the x-linked kabuki syndrome (ks2). *Clin Genet* **2015**, *87*, 252-258.

97. Micale, L.; Augello, B.; Maffeo, C.; Selicorni, A.; Zucchetti, F.; Fusco, C.; De Nittis, P.; Pellico, M.T.; Mandriani, B.; Fischetto, R.*, et al.* Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of kabuki syndrome patients. *Hum Mutat* **2014**, *35*, 841-850.

98. Van Laarhoven, P.M.; Neitzel, L.R.; Quintana, A.M.; Geiger, E.A.; Zackai, E.H.; Clouthier, D.E.; Artinger, K.B.; Ming, J.E.; Shaikh, T.H. Kabuki syndrome genes kmt2d and kdm6a: Functional analyses demonstrate critical roles in craniofacial, heart and brain development. *Hum Mol Genet* **2015**, *24*, 4443-4453.

99. Miyake, N.; Mizuno, S.; Okamoto, N.; Ohashi, H.; Shiina, M.; Ogata, K.; Tsurusaki, Y.; Nakashima, M.; Saitsu, H.; Niikawa, N.*, et al.* Kdm6a point mutations cause kabuki syndrome. *Hum Mutat* **2013**, *34*, 108-110.

100. van Haaften, G.; Dalgliesh, G.L.; Davies, H.; Chen, L.; Bignell, G.; Greenman, C.; Edkins, S.; Hardy, C.; O'Meara, S.; Teague, J.*, et al.* Somatic mutations of the histone h3k27 demethylase gene utx in human cancer. *Nat Genet* **2009**, *41*, 521-523.

101. Miyake, N.; Koshimizu, E.; Okamoto, N.; Mizuno, S.; Ogata, T.; Nagai, T.; Kosho, T.; Ohashi, H.; Kato, M.; Sasaki, G.*, et al.* Mll2 and kdm6a mutations in patients with kabuki syndrome. *Am J Med Genet A* **2013**, *161A*, 2234-2243.

102. Lederer, D.; Shears, D.; Benoit, V.; Verellen-Dumoulin, C.; Maystadt, I. A three generation x-linked family with kabuki syndrome phenotype and a frameshift mutation in kdm6a. *Am J Med Genet A* **2014**, *164A*, 1289-1292.

103. Frans, G.; Meyts, I.; Devriendt, K.; Liston, A.; Vermeulen, F.; Bossuyt, X. Mild humoral immunodeficiency in a patient with x-linked kabuki syndrome. *Am J Med Genet A* **2016**, *170*, 801-803.

104. Masui, D.; Fukahori, S.; Mizuochi, T.; Watanabe, Y.; Fukui, K.; Ishii, S.; Saikusa, N.; Hashizume, N.; Higashidate, N.; Sakamoto, S.*, et al.* Cystic biliary atresia with paucity of bile ducts and gene mutation in kdm6a: A case report. *Surg Case Rep* **2019**, *5*, 132.

105. Cheon, C.K.; Sohn, Y.B.; Ko, J.M.; Lee, Y.J.; Song, J.S.; Moon, J.W.; Yang, B.K.; Ha, I.S.; Bae, E.J.; Jin, H.S.*, et al.* Identification of kmt2d and kdm6a mutations by exome sequencing in korean patients with kabuki syndrome. *J Hum Genet* **2014**, *59*, 321-325.

106. Yavarna, T.; Al-Dewik, N.; Al-Mureikhi, M.; Ali, R.; Al-Mesaifri, F.; Mahmoud, L.; Shahbeck, N.; Lakhani, S.; AlMulla, M.; Nawaz, Z.*, et al.* High diagnostic yield of clinical exome sequencing in middle eastern patients with mendelian disorders. *Hum Genet* **2015**, *134*, 967-980.

107. Abidi, F.; Miano, M.; Murray, J.; Schwartz, C. A novel mutation in the phf8 gene is associated with x-linked mental retardation with cleft lip/cleft palate. *Clin Genet* **2007**, *72*, 19-22.

108. Laumonnier, F.; Holbert, S.; Ronce, N.; Faravelli, F.; Lenzner, S.; Schwartz, C.E.; Lespinasse, J.; Van Esch, H.; Lacombe, D.; Goizet, C.*, et al.* Mutations in phf8 are associated with x linked mental retardation and cleft lip/cleft palate. *J Med Genet* **2005**, *42*, 780-786.

109. Koivisto, A.M.; Ala-Mello, S.; Lemmela, S.; Komu, H.A.; Rautio, J.; Jarvela, I. Screening of mutations in the phf8 gene and identification of a novel mutation in a finnish family with xlmr and cleft lip/cleft palate. *Clin Genet* **2007**, *72*, 145-149.

110. Nava, C.; Lamari, F.; Heron, D.; Mignot, C.; Rastetter, A.; Keren, B.; Cohen, D.; Faudet, A.; Bouteiller, D.; Gilleron, M.*, et al.* Analysis of the chromosome x exome in patients with autism spectrum disorders identified novel candidate genes, including tmlhe. *Transl Psychiatry* **2012**, *2*, e179.

111. De Wolf, V.; Crepel, A.; Schuit, F.; van Lommel, L.; Ceulemans, B.; Steyaert, J.; Seuntjens, E.; Peeters, H.; Devriendt, K. A complex xp11.22 deletion in a patient with syndromic autism: Exploration of fam120c as a positional candidate gene for autism. *Am J Med Genet A* **2014**, *164A*, 3035-3041.